MarketPulse
D

$DASTY

12 articles found
7 positive
0 negative
5 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Dassault Systèmes

Dassault Systèmes Sets May 20 General Assembly; Shareholder Documents Now Available

Dassault Systèmes schedules May 20, 2026 shareholder assembly in Vélizy-Villacoublay with preparatory documents now available to investors.
DASTYinvestor relationsshareholder meeting
GlobeNewswire Inc.GlobeNewswire Inc.··Dassault Systèmes

Dassault Systèmes Sets May 2026 Shareholder Meeting as Q1 Results Track to Plan

Dassault Systèmes scheduled May 20 shareholder meeting with preliminary documents released. Q1 2026 results aligned with objectives; full-year outlook confirmed.
DASTYUniversal Registration DocumentQ1 2026 results
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Biosimulation Market to Hit $20B by 2034 as Drug Developers Embrace Virtual Trials

Global biosimulation market projected to expand from $4.7B in 2025 to $20B by 2034 at 17% CAGR, driven by regulatory support and virtual trial adoption.
DASTYSLPCERTSDGRdrug developmentprecision medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Dassault Systèmes

Dassault Systèmes Reports Share Count, Voting Rights in Regulatory Filing

Dassault Systèmes files regulatory disclosure showing 1.34 billion shares and 2.01 billion voting rights as of March 31, 2026, in standard French market compliance.
DASTYregulatory compliancevoting rights
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dassault Systèmes Discloses Share Capital Composition; 1.34B Shares Outstanding

Dassault Systèmes reports 1.34 billion shares outstanding and 2.01 billion voting rights as of March 31, 2026, in compliance with French regulatory requirements.
DASTYvoting rightsMarch 31, 2026
GlobeNewswire Inc.GlobeNewswire Inc.··Bcc Research

Life Sciences Validation Market Poised to Hit $3.9B by 2030 Amid Regulatory Push

Life sciences validation market projected to grow from $2.7B (2024) to $3.9B (2030) at 6.7% CAGR, driven by regulatory demands and digital transformation.
IBMTMODASTYSGSOYregulatory complianceIndustry 4.0
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dassault Systèmes Proposes €0.27 Dividend as AI Strategy Drives Growth

Dassault Systèmes proposes €0.27 per share dividend for 2025, underscoring confidence in AI strategy and digital twin technology growth across manufacturing and life sciences sectors.
DASTYartificial intelligencedividend announcement
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dassault Systèmes Proposes €0.27 Dividend as AI Strategy Drives Growth

Dassault Systèmes proposes €0.27 per share dividend for 2025, emphasizing AI-native industrial platform strategy and sustainable profitable growth.
DASTYinfrastructureartificial intelligence
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dassault Systèmes Reports Share Capital, Voting Rights in Regulatory Filing

Dassault Systèmes disclosed 1.34 billion outstanding shares and 2.01 billion total voting rights as of February 28, 2026, reflecting its dual-class share structure.
DASTYregulatory compliancevoting rights
GlobeNewswire Inc.GlobeNewswire Inc.··Dassault Systèmes

Dassault Systèmes Discloses Share Count and Voting Rights Ahead of Spring Shareholder Season

Dassault Systèmes reports 1.34 billion outstanding shares and 2.01 billion voting rights as of February 28, 2026, in regulatory compliance.
DASTYregulatory compliancevoting rights
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Medidata Earns Top 'Luminary' AI Rating as Solutions Back 80% of FDA Drug Approvals

Medidata secures top 'Luminary' AI rating from Everest Group, supporting 80% of FDA approvals with up to 37% faster patient enrollment.
DASTYagentic AIclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Healthcare Digital Twins Market Poised for 31-Fold Growth to Nearly $70B by 2035

Healthcare digital twins market expected to surge from $2.22B in 2025 to $69.67B by 2035, driven by AI integration and precision medicine adoption.
NVDAMSFTIBMPHGDASTY+1precision medicinemedical devices